| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Developmental Therapeutics, Greenebaum Cancer Center [M. J. E., D. M. R., J. H. W., J. L. E.], Division of Hematology/Oncology, Departments of Medicine [M. J. E.] and Pathology [J. L. E.], University of Maryland School of Medicine, Baltimore, Maryland 21201; Instrumentation and Biophysics Branch, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Washington, DC 20204 [S. M. M.]; and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201 [P. S. C.]
17-(Allylamino)-17-demethoxygeldanamycin (17AAG), a compound that is proposed for clinical development, shares the ability of geldanamycin to bind to heat shock protein 90 and GRP94, thereby depleting cells of p185erbB2, mutant p53, and Raf-1. Urine and plasma from mice treated i.v. with 17AAG contained six materials with absorption spectra similar to that of 17AAG. Therefore, in vitro metabolism of 17AAG by mouse and human hepatic preparations was studied to characterize: (a) the enzymes responsible for 17AAG metabolism; and (b) the structures of the metabolites produced. These materials had retention times on high-performance liquid chromatography of approximately 2, 4, 5, 6, 7, and 9 min. When incubated in an aerobic environment with 17AAG, murine hepatic supernatant (9000 x g) produced each of these compounds; the 4-min metabolite was the major product. This metabolism required an electron donor, and NADPH was favored over NADH. Metabolic activity resided predominantly in the microsomal fraction. Metabolism was decreased by 
80% in anaerobic conditions and was essentially ablated by CO. Microsomes prepared from human livers produced essentially the same metabolites as produced by murine hepatic microsomes, but the 2-min metabolite was the major product, and the 4-min metabolite was next largest. There was no metabolism of 17AAG by human liver cytosol. Metabolism of 17AAG by human liver microsomes also required an electron donor, with NADPH being preferred over NADH, was inhibited by 80% under anaerobic conditions, and was essentially ablated by CO. Liquid chromatography/mass spectrometry analysis of human and mouse in vitro reaction mixtures indicated the presence of materials with molecular weights of 545, 601, and 619, compatible with 17-(amino)-17-demethoxygeldanamycin (17AG), an epoxide, and a diol, respectively. The metabolite with retention time of 4 min was identified as 17AG by cochromatography and mass spectral concordance with authentic standard. Human microsomal metabolism of 17AAG was inhibited by ketoconazole, implying 3A4 as the responsible cytochrome P450 isoform. Incubation of 17AAG with cloned CYP3A4 produced metabolites 4 and 6. Incubation of 17AAG with cloned CYP3A4 and cloned microsomal epoxide hydrolase produced metabolites 2 and 4, with greatly decreased amounts of metabolite 6. Incubation of 17AAG with human hepatic microsomes and cyclohexene oxide, a known inhibitor of microsomal epoxide hydrolase, did not affect the production of metabolite 4 but decreased the production of metabolite 2 while increasing the production of metabolite 6. These data imply that metabolite 2 is a diol and metabolite 6 is an epoxide. Mass spectral fragmentation patterns and the fact that 17AG is not metabolized argue for the epoxide and diol being formed on the 17-allylamino portion of 17AAG and not on its ansamycin ring. These data have implications with regard to preclinical toxicology and activity testing of 17AAG as well as its proposed clinical development because: (a) production of 17AG requires concomitant production of acrolein from the cleaved allyl moiety; and (b) 17AG, which was not metabolized by microsomes, has been described as being as active as 17AAG in decreasing cellular p185erbB2.
1 Supported by Contract NO1-CM57199 awarded by the National Cancer Institute, NIH, Bethesda, MD 20892, J. W. was the recipient of a Mildred C. Hoffberger Summer Student Fellowship.
2 To whom requests for reprints should be addressed, at Greenebaum Cancer Center, 9-024 Bressler Research Laboratories, 655 West Baltimore Street, Baltimore, MD 21201. Phone: (410) 328-3685; Fax: (410) 328-6559; E-mail: megorin@umabnet.ab.umd.edu.
Received 10/ 6/97. Accepted 4/ 1/98.
This article has been cited by other articles:
|
|
 |
|
  S. N. Shelton, M. E. Shawgo, S. B. Matthews, Y. Lu, A. C. Donnelly, K. Szabla, M. Tanol, G. A. Vielhauer, R. A. Rajewski, R. L. Matts, et al. KU135, a Novel Novobiocin-Derived C-Terminal Inhibitor of the 90-kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic Cells Mol. Pharmacol., December 1, 2009; 76(6): 1314 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tokui, H. Adachi, M. Waza, M. Katsuno, M. Minamiyama, H. Doi, K. Tanaka, J. Hamazaki, S. Murata, F. Tanaka, et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse Hum. Mol. Genet., March 1, 2009; 18(5): 898 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Guo, P. Reigan, D. Siegel, and D. Ross Enzymatic Reduction and Glutathione Conjugation of Benzoquinone Ansamycin Heat Shock Protein 90 Inhibitors: Relevance for Toxicity and Mechanism of Action Drug Metab. Dispos., October 1, 2008; 36(10): 2050 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Eccles, A. Massey, F. I. Raynaud, S. Y. Sharp, G. Box, M. Valenti, L. Patterson, A. de Haven Brandon, S. Gowan, F. Boxall, et al. NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis Cancer Res., April 15, 2008; 68(8): 2850 - 2860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Ramanathan, M. J. Egorin, J. L. Eiseman, S. Ramalingam, D. Friedland, S. S. Agarwala, S. P. Ivy, D. M. Potter, G. Chatta, E. G. Zuhowski, et al. Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers Clin. Cancer Res., March 15, 2007; 13(6): 1769 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bagatell, L. Gore, M. J. Egorin, R. Ho, G. Heller, N. Boucher, E. G. Zuhowski, J. A. Whitlock, S. P. Hunger, A. Narendran, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study Clin. Cancer Res., March 15, 2007; 13(6): 1783 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Weigel, S. M. Blaney, J. M. Reid, S. L. Safgren, R. Bagatell, J. Kersey, J. P. Neglia, S. P. Ivy, A. M. Ingle, L. Whitesell, et al. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study Clin. Cancer Res., March 15, 2007; 13(6): 1789 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Sharp, K. Boxall, M. Rowlands, C. Prodromou, S. M. Roe, A. Maloney, M. Powers, P. A. Clarke, G. Box, S. Sanderson, et al. In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors Cancer Res., March 1, 2007; 67(5): 2206 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Smith, F. I. Raynaud, and P. Workman The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery Mol. Cancer Ther., February 1, 2007; 6(2): 428 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Lang, G. W. Caldwell, J. Li, G. C. Leo, W. J. Jones, and J. A. Masucci Biotransformation of Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin by Human Liver Microsomes: Reductive versus Oxidative Metabolism and Implications Drug Metab. Dispos., January 1, 2007; 35(1): 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V Powers and P. Workman Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S125 - S135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Sydor, E. Normant, C. S. Pien, J. R. Porter, J. Ge, L. Grenier, R. H. Pak, J. A. Ali, M. S. Dembski, J. Hudak, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 PNAS, November 14, 2006; 103(46): 17408 - 17413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Nowakowski, A. K. McCollum, M. M. Ames, S. J. Mandrekar, J. M. Reid, A. A. Adjei, D. O. Toft, S. L. Safgren, and C. Erlichman A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6087 - 6093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross The Bioreduction of a Series of Benzoquinone Ansamycins by NAD(P)H:Quinone Oxidoreductase 1 to More Potent Heat Shock Protein 90 Inhibitors, the Hydroquinone Ansamycins Mol. Pharmacol., October 1, 2006; 70(4): 1194 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Smith, A. Hayes, K. James, B. P. Nutley, E. McDonald, A. Henley, B. Dymock, M. J. Drysdale, F. I. Raynaud, and P. Workman Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol. Cancer Ther., June 1, 2006; 5(6): 1628 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. H. Arlander, S. J. Felts, J. M. Wagner, B. Stensgard, D. O. Toft, and L. M. Karnitz Chaperoning Checkpoint Kinase 1 (Chk1), an Hsp90 Client, with Purified Chaperones J. Biol. Chem., February 3, 2006; 281(5): 2989 - 2998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Dote, D. Cerna, W. E. Burgan, K. Camphausen, and P. J. Tofilon ErbB3 Expression Predicts Tumor Cell Radiosensitization Induced by Hsp90 Inhibition Cancer Res., August 1, 2005; 65(15): 6967 - 6975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Banerji, A. O'Donnell, M. Scurr, S. Pacey, S. Stapleton, Y. Asad, L. Simmons, A. Maloney, F. Raynaud, M. Campbell, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies J. Clin. Oncol., June 20, 2005; 23(18): 4152 - 4161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Ramanathan, D. L. Trump, J. L. Eiseman, C. P. Belani, S. S. Agarwala, E. G. Zuhowski, J. Lan, D. M. Potter, S. P. Ivy, S. Ramalingam, et al. Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers Clin. Cancer Res., May 1, 2005; 11(9): 3385 - 3391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Grem, G. Morrison, X.-D. Guo, E. Agnew, C. H. Takimoto, R. Thomas, E. Szabo, L. Grochow, F. Grollman, J. M. Hamilton, et al. Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors J. Clin. Oncol., March 20, 2005; 23(9): 1885 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Goetz, D. Toft, J. Reid, M. Ames, B. Stensgard, S. Safgren, A. A. Adjei, J. Sloan, P. Atherton, V. Vasile, et al. Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer J. Clin. Oncol., February 20, 2005; 23(6): 1078 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. WORKMAN Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 499 - 515. [Abstract] [PDF]
|
|
|
|
|
|
E. E. A. Bull, H. Dote, K. J. Brady, W. E. Burgan, D. J. Carter, M. A. Cerra, K. A. Oswald, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin Clin. Cancer Res., December 1, 2004; 10(23): 8077 - 8084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kaur, D. Belotti, A. M. Burger, K. Fisher-Nielson, P. Borsotti, E. Riccardi, J. Thillainathan, M. Hollingshead, E. A. Sausville, and R. Giavazzi Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator Clin. Cancer Res., July 15, 2004; 10(14): 4813 - 4821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Holleran, J. Fourcade, M. J. Egorin, J. L. Eiseman, R. A. Parise, S. M. Musser, K. D. White, J. M. Covey, G. L. Forrest, and S.-S. Pan IN VITRO METABOLISM OF THE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR, WORTMANNIN, BY CARBONYL REDUCTASE Drug Metab. Dispos., May 1, 2004; 32(5): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Nielsen, H. N. Andrews, M. Cheang, J. E. Kucab, F. D. Hsu, J. Ragaz, C. B. Gilks, N. Makretsov, C. D. Bajdik, C. Brookes, et al. Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival: Potential for Intervention with 17-Allylamino Geldanamycin Cancer Res., January 1, 2004; 64(1): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Goetz, D. O. Toft, M. M. Ames, and C. Erlichman The Hsp90 chaperone complex as a novel target for cancer therapy Ann. Onc., August 1, 2003; 14(8): 1169 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Workman Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics Mol. Cancer Ther., February 1, 2003; 2(2): 131 - 138. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Solit, F. F. Zheng, M. Drobnjak, P. N. Munster, B. Higgins, D. Verbel, G. Heller, W. Tong, C. Cordon-Cardo, D. B. Agus, et al. 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts Clin. Cancer Res., May 1, 2002; 8(5): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Kelland, S. Y. Sharp, P. M. Rogers, T. G. Myers, and P. Workman DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90 J Natl Cancer Inst, November 17, 1999; 91(22): 1940 - 1949. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
